» Articles » PMID: 33545386

False-Negative Results in Lung Cancer Screening-Evidence and Controversies

Overview
Journal J Thorac Oncol
Publisher Elsevier
Date 2021 Feb 5
PMID 33545386
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Identifying false-negative cases is an important quality metric in lung cancer screening, but it has been infrequently and variably reported in previous studies. Although as a proportion of all screening participants, false-negative cases are uncommon, such cases may constitute a substantial proportion of all lung cancers diagnosed (up to 15%) within a screening program. This article reviews the impact and causes of false-negative lung cancer screening tests, including those related to radiologic evaluation, nodule management protocols, and management decisions made by multidisciplinary teams. Following a review of data from international screening studies, this article discusses the controversies within the screening literature surrounding the definition and classification of a false-negative lung cancer screening test and how data on false-negative rates should be captured and recorded. Challenges, such as avoiding overly cautious surveillance of lung nodules while minimizing overdiagnosis and investigation of indolent or benign lesions, are considered. Finally, the advantages and disadvantages of different approaches to dealing with false-negative results in lung cancer screening are discussed.

Citing Articles

Minimally invasive biomarkers for triaging lung nodules-challenges and future perspectives.

Afridi W, Picos S, Bark J, Stamoudis D, Vasani S, Irwin D Cancer Metastasis Rev. 2025; 44(1):29.

PMID: 39888565 PMC: 11785609. DOI: 10.1007/s10555-025-10247-5.


Artificial intelligence in precision medicine for lung cancer: A bibliometric analysis.

Wang Y, Zhang W, Liu X, Tian L, Li W, He P Digit Health. 2025; 11:20552076241300229.

PMID: 39758259 PMC: 11696962. DOI: 10.1177/20552076241300229.


Discrimination of Lung Cancer and Benign Lung Diseases Using BALF Exosome DNA Methylation Profile.

Batochir C, Kim I, Jo E, Kim E, Kim H, Hur J Cancers (Basel). 2024; 16(15).

PMID: 39123492 PMC: 11311347. DOI: 10.3390/cancers16152765.


Navigating the Pitfalls of Lung Cancer Screening: A Case Study on the Risks and Costs of Negative Screenings.

Shabpiray H, George J, Patel S, Askari M Cureus. 2024; 16(5):e59844.

PMID: 38854349 PMC: 11157477. DOI: 10.7759/cureus.59844.


Cancer Screening: Present Recommendations, the Development of Multi-Cancer Early Development Tests, and the Prospect of Universal Cancer Screening.

Gales L, Paun M, Anghel R, Trifanescu O Cancers (Basel). 2024; 16(6).

PMID: 38539525 PMC: 10969110. DOI: 10.3390/cancers16061191.